Enhancement of docetaxel solubility via conjugation of Formulation- compatible moieties

Organic and Biomolecular Chemistry

Volumn 7, Issue 17, 2009, Pages 3437-3446

  Huynh, Loan ^a   Leroux, Jean Christophe ^b,c   Allen, Christine ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b ETH ZURICH   (Switzerland)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL GROUP; CANCER CELLS; DOCETAXEL; DRUG ENTRAPMENT; DRUG LOADING CAPACITY; ESTER BONDS; ESTER LINKAGES; FORMULATION DEVELOPMENT; HUMAN CANCER CELLS; IMPROVED SOLUBILITY; INTERNAL PHASE; NANOEMULSION; PRODRUGS; THEORETICAL CALCULATIONS;

CELL CULTURE; CELL MEMBRANES; CHEMICAL MODIFICATION; CYTOTOXICITY; EMULSIFICATION; EMULSIONS; ESTERIFICATION; ESTERS; ISOMERS; SOLUBILITY; STRATEGIC PLANNING; TERNARY SYSTEMS;

DRUG PRODUCTS;

ANTINEOPLASTIC AGENT; DOCETAXEL; LAURIC ACID; LAURIC ACID DERIVATIVE; OIL; PRODRUG; TAXOID;

ARTICLE; CHEMISTRY; DRUG DESIGN; EMULSION; HUMAN; HYDROLYSIS; SOLUBILITY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DESIGN; EMULSIONS; HUMANS; HYDROLYSIS; LAURIC ACIDS; OILS; PRODRUGS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TAXOIDS;

EID: 70349383376     PISSN: 14770520     EISSN: None     Source Type: Journal    
DOI: 10.1039/b906862g     Document Type: Article

References (53)

1. C. A. Lipinski Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 2000 44 235 249
2. L. C. Collins-Gold R. T. Lyons L. C. Bartholow Parenteral emulsions for drug delivery Adv. Drug Delivery Rev. 1990 5 189 208
3. P. P. Constantinides M. V. Chaubal R. Shorr Advances in lipid nanodispersions for parenteral drug delivery and targeting Adv. Drug Delivery Rev. 2008 60 757 767
4. D. L. Garrec S. Gori L. Luo D. Lessard D. C. Smith M.-A. Yessine M. Ranger J.-C. Leroux Poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation J. Controlled Release 2004 99 83 101
5. T. Negishi F. Koizumi H. Uchino J. Kuroda T. Kawaguchi S. Naito Y. Matsumura NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel Br. J. Cancer 2006 95 601 606
6. T. Nakanishi S. Fukushima K. Okamoto M. Suzuki Y. Matsumura M. Yokoyama T. Okano Y. Sakurai K. Kataoka Development of the polymer micelle carrier system for doxorubicin J. Controlled Release 2001 74 295 302
7. B. B. Lundberg V. Risovic M. Ramaswamy K. M. Wasan A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration J. Controlled Release 2003 86 93 100
8. J. Liu Y. Xiao C. Allen Polymer-drug compatibility: A guide to the development of delivery systems for the anticancer agent, ellipticine J. Pharm. Sci. 2003 23 132 143
9. L. Huynh J. Grant J. C. Leroux P. Delmas C. Allen Predicting the solubility of the anti-cancer agent docetaxel in small molecule excipients using computational methods Pharm. Res. 2008 25 147 157
10. M. L. Forrest J. A. Yãñez C. M. Remsberg Y. Ohgami G. S. Kwon N. M. Davies Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(e-caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity Pharm. Res. 2008 25 194 206
11. M. O. Bradley N. L. Webb F. H. Anthony P. Devanesan P. A. Witman S. Hemamalini M. C. Chander S. D. Baker L. He S. B. Horwitz C. S. Swindell Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel Clin. Cancer Res. 2001 7 3229 3238
12. K. L. Hennenfent R. Govindan Novel formulations of taxanes: a review. Old wine in a new bottle? Ann. Oncol. 2006 17 735 749
13. J. E. Cortes R. Pazdur Docetaxel J. Clin. Oncol. 1995 13 2643 2655
14. E. K. Rowinsky R. C. Donehower Drug therapy: Paclitaxel (Taxol) N. Engl. J. Med. 1995 332 1004 1014
15. ®) Cancer Treat. Rev. 1993 19 351 386
16. L. B. Michaud V. Valero G. Hortobagyi Risks and benefits of taxanes in breast and ovarian cancer Drug Saf. 2000 23 401 428
17. V. Valero S. F. Jones D. D. V. Hoff D. J. Booser R. G. Mennel P. M. Ravdin F. A. Holmes Z. Rahman M. W. Schottstaedt J. K. Erban L. Esparza-Guerra R. H. Earhart G. N. Hortobagyi H. A. B. 3rd A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer J. Clin. Oncol. 1998 16 3362 3368 (Pubitemid 28481633)
18. J. Crown M. O'leary W. S. Ooi Docetaxel and paclitaxel in the treatment of breast cancer: A review of clinical experience The Oncologist 2004 9 Suppl 2 24 32
19. P. G. Rose J. A. Blessing H. G. Ball J. Hoffman D. Warshal K. DeGeest D. H. Moore A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study Gynecol. Oncol. 2003 88 130 135
20. C. F. Verschraegen T. Sittisomwong A. P. Kudelka E. d. Guedes M. Steger T. T. Nelson M. Vincent R. Rogers E. N. Atkinson J. J. Kavanagh Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma J Clin Oncol. 2000 18 2733 2739
21. L. R. Kelland G. Abel Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and-resistant human ovarian carcinoma cell lines Cancer Chemother. Pharmacol. 1992 30 444 450
22. L. Zuylen J. Verweij A. Sparreboom Role of formulation vehicles in taxane pharmacology Invest. New Drugs 2001 19 125 141
23. M. Bergh K. Magnusson J. L. Nilsson A. T. Karlberg Contact allergenic activity of Tween 80 before and after air exposure Contact Dermatitis 1997 37 9 18
24. W. B. Shelley N. Talanin E. D. Shelley Polysorbate 80 hypersensitivity Lancet 1995 345 1312 1313
25. J. S. Coon W. Knudson K. Clodfelter B. Lu R. S. Weinstein Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance Cancer Res. 1991 51 897 902
26. J. Rossi S. Giasson M. N. Khalid P. Delmas C. Allen J.-C. Leroux Long-circulating poly(ethylene glycol)-coated emulsions to target solid tumors Eur. J. Pharm. Biopharm. 2007 67 329 338
27. M. N. Khalid P. Simard D. Hoarau A. Dragomir J.-C. Leroux Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors Pharm. Res. 2006 23 752 758
28. A. K. Ghose G. M. Crippen Atomic physicochemical parameters for three-dimensional structure-directed quantitative structure-activity relationships I. Partition, coefficients as a measure of hydrophobicity J. Comput. Chem. 1986 7 565 577
29. R. F. Fedors A method for estimating both the solubility parameters and molar volumes of liquids Polym. Eng. Sci. 1974 14 147 154
30. M. È. Perron F. Plourde S. Guérard L. Huynh C. Allen J.-C. Leroux An investigation on the use of tributyrin nanoemulsions for docetaxel delivery J. Drug Del. Sci. Tech. 2008 18 189 195
31. S. R. Dipali S. B. Kulkarni G. V. Betageri Comparative study of separation of non-encapsulated drug from unilamellar liposomes by various methods J. Pharm. Pharmacol. 1996 48 1112 1115
32. J. Liu P. Zahedi F. Zeng C. Allen Nano-sized assemblies of a PEG-docetaxel conjugate as a delivery strategy for docetaxel J. Pharm. Sci. 2008 97 3274 3290
33. M. G. Carstens P. H. J. L. F. d. Jong C. F. v. Nostrum J. Kemmink R. Verrijk L. G. J. d. Leede D. J. A. Crommelin W. E. Hennink The effect of core composition in biodegradable oligomeric micelles as taxane formulations Eur. J. Pharm. Biopharm. 2008 68 596 606
34. T. M. Lima C. C. Kanunfre C. Pompéia R. Verlengia R. Curi Ranking the toxicity of fatty acids on Jurkat and Raji cells by flow cytometric analysis Toxicol. in Vitro 2002 16 741 747
35. B. T. Hill R. D. H. Whelan S. A. Shellard S. Mcclean L. K. Hosking Differential cytotoxic effects of docetaxel in a range of mammalian tumor-cell lines and certain drug-resistant sublines in-vitro Invest. New Drugs 1994 12 3 169 182
36. M. L. Immordino P. Brusa F. Rocco S. Arpicco M. Ceruti L. Cattel Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs J. Controlled Release 2004 100 331 336
37. R. V. Dev J. M. Babu K. Vyas P. S. Ram P. Ramachandra N. M. Sekhar D. N. M. Reddy N. S. Rao Isolation and characterization of impurities in docetaxel J. Pharm. Biomed. Anal. 2006 40 614 622
38. C. Li D. F. Yu R. A. Newman; F. Cabral L. C. Stephens N. Hunter L. Milas S. Wallace Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate Cancer Res. 1998 58 2404 2409
39. H. Lee K. Lee T. G. Park Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity Bioconjugate Chem. 2008 19 1319 1325
40. 1 Water-soluble prodrugs of taxol with potent antitumor activity J. Med. Chem. 1989 32 788 792
41. J. M. G. Cowie, Polymers: Chemistry and Physics of Modern Materials, 2nd edn, Nelson Thornes Ltd, Cheltenham, 1991, ch. 8
42. F. Q. Hu G. F. Ren H. Yuan Y. Z. Du S. Zeng Shell cross-linked stearic acid grafted chitosan oligosaccharide self-aggregated micelles for controlled release of paclitaxel Colloids Surf., B 2006 50 97 103
43. A. N. Lukyanov V. P. Torchilin Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs Adv. Drug Delivery Rev. 2004 56 1273 1289
44. M. Lovreka B. Zorc B. Boneschansb I. Butula Macromolecular prodrugs. VIII. Synthesis, of polymer-gemfibrozil conjugates Int. J. Pharm. 2000 200 59 66
45. Z. Gao A. N. Lukyanov A. Singhal V. P. Torchilin Diacylpolymer micelles as nanocarriers for poorly soluble anticancer drugs Nano Lett. 2002 2 979 982
46. T. Ganesh Improved biochemical strategies for targeted delivery of taxoids Bioorg. Med. Chem. 2007 15 3597 3623
47. J. Parness D. G. I. Kingston R. G. Powell C. Harracksingh S. B. Horwitz Structure-activity study of cytotoxicity and microtubule assembly image by taxol and related taxanes Biochem. Biophys. Res. Commun. 1982 105 1082 1089
48. E. W. P. Damen P. H. G. Wiegerinck L. Braamer D. Sperling D. d. Vos H. W. Scheeren Paclitaxel esters of malic acid as prodrugs with improved water solubility Bioorg. Med. Chem. 2000 8 427 432
49. S. Ali I. Ahmad A. Peters G. Masters S. Minchey A. Janoff E. Mayhew Hydrolyzable hydrophobic taxanes: synthesis and anti-cancer activities Anti-Cancer Drugs 2001 12 117 128
50. T. A. Kirschberg C. L. VanDeusen J. B. Rothbard M. Yang P. A. Wender Arginine-based molecular transporters: the synthesis and chemical evaluation of releasable taxol-transporter conjugates Org. Lett. 2003 5 3459 3462
51. I. Ojima S. D. Kuduk P. Pera J. M. Veith R. J. Bernacki Synthesis and structure-activity relationships of nonaromatic taxoids: effects of alkyl and alkenyl ester groups on cytotoxicity J. Med. Chem. 1997 40 279 285
52. W. Mellado N. F. Magri D. G. I. Kingston R. Garcia-Arenas G. A. Orr S. B. Horwitz Preparation and biological activity of taxol acetates Biochem. Biophys. Res. Commun. 1984 124 329 336
53. G. Cavallaro M. Licciardi P. Caliceti S. Salmaso G. Giammona Synthesis, physico-chemical and biological characterization of a paclitaxel macromolecular prodrug Eur. J. Pharm. Biopharm. 2004 58 151 159